The Hindu·2 min read·medium
India’s first dengue vaccine arrives with a crucial safety caveat
S
Swaminathan S
✦AI Summary
India has approved the dengue vaccine Qdenga, manufactured by Takeda, for use in individuals aged 4-60. While the vaccine covers all four dengue serotypes, clinical trial data has raised specific safety concerns that regulators are monitoring.
India’s drug regulator just approved the country’s first dengue vaccine, Qdenga. It is designed and claimed to protect against the four serotypes of the dengue-causing virus, called DENV-1 to DENV-4. Young children as well as adults (aged 4-60 years), irrespective of whether they have had dengue before, may be vaccinated with Qdenga.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in